"label","name","description","instanceType","rationale","uuid:ID","id"
"","Study Design 1","The main design for the study","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","9fdb5a3e-cc06-4696-9cd8-2fd18075612f","StudyDesign_1"
